Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
about
Safety of human papillomavirus vaccines: a reviewAntibody Persistence in Adults Two Years after Vaccination with an H1N1 2009 Pandemic Influenza Virus-Like Particle Vaccine.Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study.A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females.Cost analysis of Human Papillomavirus-related cervical diseases and genital warts in SwazilandPerspectives for preventive and therapeutic HPV vaccines.Living on three time scales: the dynamics of plasma cell and antibody populations illustrated for hepatitis a virus.Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years.HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future.Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary.Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, TanzaniaAntibody persistence and T-cell balance: two key factors confronting HIV vaccine development.Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection.Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov modelThe impact of HPV female immunization in Italy: model based predictions.HPV - immune response to infection and vaccinationEfficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model.Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 yearsVaccination of boys or catch-up of girls above 11 years of age with the HPV-16/18 AS04-adjuvanted vaccine: where is the greatest benefit for cervical cancer prevention in Italy?Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15-55 years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study.Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial.Cross-sectional study about primary health care professionals views on the inclusion of the vaccine against human papillomavirus in the vaccine schedules.Emerging therapeutic targets in metastatic progression: A focus on breast cancer.Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccinationNew Approaches to Immunotherapy for HPV Associated Cancers.Human Papillomavirus (HPV) Infections and the Importance of HPV Vaccination.National- and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United StatesProjected impact of Cervarix™ vaccination on oncogenic human papillomavirus infection and cervical cancer in the United KingdomHuman papillomavirus vaccine: widening the scope for cancer prevention.Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems.Review: current knowledge on the role of HPV antibodies after natural infection and vaccination: implications for monitoring an HPV vaccination programme.Strategies for continuous evaluation of the benefit-risk profile of HPV-16/18-AS04-adjuvanted vaccine.Human papillomavirus vaccines: key factors in planning cost-effective vaccination programs.Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials.Tumour virus vaccines: hepatitis B virus and human papillomavirus.Cost-effectiveness of human papillomavirus vaccination in Germany.Projected impact of Cervarix® vaccination on oncogenic human papillomavirus infection and cervical cancer in the United Kingdom.Uptake of the HPV vaccination programme in England: a cross-sectional survey of young women attending sexual health services.
P2860
Q28082119-7D960068-0EC9-407C-A3A6-52D79E344CB5Q30384943-4D0C924F-B93E-4970-AC99-2D4DF88781B1Q30980654-1B13EB0E-886D-4290-9270-EAE185D64F00Q33514126-1F0341A2-C73B-4FFE-B2FB-3DEFDA74EC9DQ33713018-BEA7CC9E-7CB6-4842-BC53-ADBF702046A6Q34011494-DE99EE8B-519D-4E0A-8636-DF6FE3058400Q34186939-B6F9BE07-3CB7-47A7-B20C-6ECFF2BB0406Q34291136-9B23E5D9-3F06-4F31-B009-5670648D3063Q34335370-740A2679-7F73-48F5-B2A0-9D06666FB372Q34461262-AD8E1014-7AE2-4E8E-9DC8-60623459B529Q34475547-D3BB2E6D-E831-47E7-9855-F696E2EB9B31Q34480617-539F0BC2-1C35-4ABD-81B6-34E930DBC828Q34580293-3B2C4A7E-52A0-4D76-966F-FD59C6C45C08Q34612818-BE1270E7-6BA1-4B2C-AECF-CE8478A4C5E2Q34894228-4E9AAD4B-BEF8-4245-A23C-846A09C83899Q35117850-AC8C4F46-521A-477F-B514-E9A373F859C3Q35180148-90BA4A78-C2D2-477F-9706-F085110F6622Q35221177-02442ED5-7378-4155-8444-B3CAA73C092FQ35235306-AC190478-90E0-4C07-9A85-AEE0A28C4060Q35577825-8422524F-041C-4C5B-886C-E72CFAF36F2AQ35779425-8E05F5CF-3FF5-4DF6-9E0E-459A3F1BDC41Q35810353-245E83DD-6D96-459F-82EB-F01040B87E03Q35886534-A65847FC-A512-44B8-A381-051CC07B88B9Q36281492-8AC78B7D-207C-42E9-9DF9-C15A03D0E48AQ36854062-65854E40-5F65-4A48-A9BE-ABBD9AD5BCCDQ36978409-0C5214F3-1974-470B-955C-B12EC3E90A7BQ37137430-277ED230-28A1-4A7E-9024-7EBFE5D28527Q37155765-4CC86ECD-F1C0-475A-BF38-2FDE49C2F46BQ37173134-13383699-7E49-4A9E-BC84-4AEB4F29206DQ37502417-1C801E52-19AF-4FCC-94E5-C37E7DD41B11Q37861634-998FB67E-1B89-4021-989E-C710AF0C4D9AQ37867102-63DF3FFB-A380-4226-83C0-43F370D20DABQ38110696-4225012C-F12A-4D7A-96A9-317325540408Q38248947-96B5AAD1-DFA9-42AF-8C3F-5CAE1335F806Q38255277-FC333CED-E8F0-4098-89AA-4FA3505751DDQ38381606-1C5ED215-5200-40EC-82EC-917085EF389AQ40046649-0931992A-6436-4307-8B83-4BDD0476097DQ40063569-2F81D5F3-8FFA-4E9E-87E2-8FDAEB6DA282Q41648405-7EB7033E-4FA0-419B-977F-E28ADCB2F2AAQ42230928-0125A2EA-4A7F-4805-B00A-802D6D5719CA
P2860
Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Long-term persistence of anti- ...... sustained antibody responses.
@en
Long-term persistence of anti- ...... sustained antibody responses.
@nl
type
label
Long-term persistence of anti- ...... sustained antibody responses.
@en
Long-term persistence of anti- ...... sustained antibody responses.
@nl
prefLabel
Long-term persistence of anti- ...... sustained antibody responses.
@en
Long-term persistence of anti- ...... sustained antibody responses.
@nl
P2093
P1433
P1476
Long-term persistence of anti- ...... sustained antibody responses.
@en
P2093
Dominique Descamps
Fabian Tibaldi
Gary Dubin
Karin Hardt
Marie-Pierre David
P356
10.1016/J.YGYNO.2009.01.011
P407
P433
P577
2009-02-12T00:00:00Z